APPLICATION
ANDA090246
TYPE
ANDA
ORIGINAL APPROVAL
2012-05-15
LATEST ACTION
2019-07-23
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued
Products
LAMIVUDINE AND ZIDOVUDINEDiscontinued
LAMIVUDINE 150MG, ZIDOVUDINE 300MG · TABLET · ORAL
Approval history
2019-07-23Labeling · Supplement 10 · standardAP
2019-07-23Labeling · Supplement 9 · standardAP
2019-07-23Labeling · Supplement 8 · standardAP
2016-09-29Labeling · Supplement 5 · standardAP
2012-05-15OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.